March 2012
Volume 53, Issue 14
ARVO Annual Meeting Abstract  |   March 2012
Inflammatory Reactions Complicating Exudative Age-Related Macular Degeneration (AMD)
Author Affiliations & Notes
  • Alena Reznik
    UC Davis Eye Center, UC Davis Eye Center, Sacramento, California
  • Charles H. Weber
    Eye Center, University of California Davis, Sacramento, California
  • David G. Telander
    Ophthalmology, University of California, Davis, Sacramento, California
  • Lawrence S. Morse
    Ophthalmology, Univ of California-Davis, Sacramento, California
  • Susanna S. Park
    Ophthalmology & Vision Science, Univ of California Davis Eye Ctr, Sacramento, California
  • Charles E. Thirkill
    Research Lab 1220 Surge III, UC Davis, Davis, California
  • Footnotes
    Commercial Relationships  Alena Reznik, None; Charles H. Weber, None; David G. Telander, None; Lawrence S. Morse, None; Susanna S. Park, None; Charles E. Thirkill, None
  • Footnotes
    Support  Research to prevent blindness.
Investigative Ophthalmology & Visual Science March 2012, Vol.53, 6465. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alena Reznik, Charles H. Weber, David G. Telander, Lawrence S. Morse, Susanna S. Park, Charles E. Thirkill; Inflammatory Reactions Complicating Exudative Age-Related Macular Degeneration (AMD). Invest. Ophthalmol. Vis. Sci. 2012;53(14):6465.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: : The efficacy of "wet" AMD treatment may be limited by secondary and superimposed inflammatory reactions to the retina or retinal pigment epithelium (RPE). Therefore we hypothesize that exudative AMD patients that do not respond to anti-vascular endothelial growth factor (VEGF) therapy may have increase inflammatory reactions to the retina and RPE. We examined both dry (40) and wet (30) AMD patients and correlated serum anti-retinal and anti-RPE reactions to AMD disease and response to therapy.

Methods: : Serum samples were collected from patients in 4 categories: normal (30 patients), non-exudative AMD (40 patients), and exudative AMD (30 patients) including poor-responder to anti-VEGF therapy. Patients with exudative AMD were enrolled for 6 months of anti-VEGF (randibizumab) therapy and serum was collected at on enrollment and at months 3 and 6. Poor-responders were defined as those patients with residual cystoid macular edema or subretinal fluid at month 4 and having less than 100 microns improvement of central retinal thickness by OCT. Western blot reactions on extracts of pig retina and in vitro cultivated human retinal pigment epithelium (ATCC ARPE-19) were used in the evaluations of patient’s antibody activity with the protein components of these tissues.

Results: : We found a series of abnormal antibody reactions to both retinal and RPE protein antigens correlating with exudative AMD and poor-response to therapy. In addition, specific reactions were noted that were previously described by others as being associated with, or suspected of being associated with immune-mediated loss of vision.

Conclusions: : Evidence of abnormal immunological activity within the eyes of treatment-refractive AMD patients may explain their failure to respond to conventional treatments is due to immunological complications suspected to be autoimmune in nature. Modifying treatments to accommodate these findings could prove beneficial in some cases of refractory AMD, especially with those involving abnormal antibody activity with recognized ocular autoantigens.

Keywords: age-related macular degeneration • immunomodulation/immunoregulation • vitreous 

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.